tci Medicare Compliance & Reimbursement - 2006 Issue 26

Oncologists: Prevent Steep Cuts To Oncology Drugs: Make Your Voice Heard

Oncology drugs overpriced by as much as 185 percent Five commonly billed oncology drugs are at least 5 percent cheaper than the prices Medicare pays physicians for them, the HHS Office of Inspector General (OIG) claims in a new survey.  The OIG claims that carboplatin (J9045) is overpriced by a startling 185.1 percent, dexamethasone sodium phosphate (J1100) is overvalued by 65.2 percent, and dolasetron mesylate (J1260) is 55.6 percent too expensive. The survey found two other drugs, vinorelbine tartrate (J9390) and granisetron HCI (J1626), also had double-digit overpayments.  The drugs were overpriced for a...

To read the full article, sign in and subscribe to tci Medicare Compliance & Reimbursement.


Keep pace with evolving Medicare regulations — and onboard your team — with timely analysis of critical updates interpreted in an easy-to-follow, easy-to-apply format. Your subscription to TCI's Medicare Compliance & Reimbursement Alert will equip you to navigate code and guideline changes, CCI edits, and revisions to modifiers, payer policies, the fee schedule, OIG target areas, and more.

  • Current newsletters added each month
  • Fully searchable archives - over 4200 articles
  • ALL years/issues back to 2003 organized by year and issue
  • Codes mentioned in articles are linked to Code Information pages
  • Code Information pages link back to related articles
Access to this feature is available in the following products:
  • tci Medicare Compliance & Reimbursement +Archives

demo
request yours today
 subscribe
start today
 newsletter
free subscription

Thank you for choosing Find-A-Code, please Sign In to remove ads.